Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes:a real-world study in the UK
| Autor: | Pratik Choudhary, Javier Castañeda, Fiona Campbell, A. Arrieta, S De Portu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Blood Glucose Male Percentile Time Factors Adolescent Databases Factual Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Biosensing Techniques Rate ratio Young Adult 03 medical and health sciences Insulin Infusion Systems 0302 clinical medicine Endocrinology Diabetes mellitus Internal Medicine medicine Humans Insulin 030212 general & internal medicine Low glucose suspend Child Glycated Hemoglobin Type 1 diabetes business.industry Blood Glucose Self-Monitoring Equipment Design medicine.disease Hypoglycemia United Kingdom Diabetes Mellitus Type 1 Treatment Outcome Median time Anesthesia Female Medical Record Linkage Minimed Paradigm business |
| Zdroj: | Choudhary, P, de Portu, S, Arrieta, A, Castañeda, J & Campbell, F M 2019, ' Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes : a real-world study in the UK ', Diabetic Medicine, vol. 36, no. 9, pp. 1100-1108 . https://doi.org/10.1111/dme.14043 |
| Popis: | Aims: To assess the efficacy of insulin pumps with automated insulin suspension systems in a real-world setting. Methods: We analysed anonymized data uploaded to CareLink™ by people (n=920) with Type 1 diabetes using the MiniMed Paradigm Veo system and the MiniMed 640G system (Medtronic International Trading Sàrl, Tolochanez, Switzerland) with SmartGuard technology, with or without automated insulin suspension enabled, between February 2016 and June 2018. Users with ≥15 days of sensor data and ≥70% sensor-wear time were classified as sensor-augmented pump alone, sensor-integrated pump with low glucose suspend enabled or sensor-integrated pump with predictive low glucose management enabled. Results: The median (25th–75th percentile) system use was 161 (58–348) days. The median time spent with sensor glucose values ≤3 mmol/l was 0.8 (0.3–1.7)% in the sensor-augmented pump group, 0.3 (0.1–0.7)% in the sensor-integrated pump with low glucose suspend group, and 0.3 (0.1–0.5)% in the sensor-integrated pump with predictive low glucose management group. In individuals switching from sensor-augmented pump to sensor-integrated pump with low glucose suspend (n=31), there were significant reductions in the monthly rate of hypoglycaemic events |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|